- Enliven prices $400M offering; Jazz drug Zepzelca fails confirmatory studyPlus news about Caribou, Adial, and the Beneluxa Initiative. 💵 Enliven Therapeutics’ data and raise: The Burlingame, CA-based biotech priced a $400 million offering {$ELVN} Thursday night after…Endpoints · 1mo ago↗ source
- Biopharma's pay oddities of 2025: Executive perks and eccentricitiesIn combing through thousands of C-suite pay packages worth billions of dollars, it’s rare for a line item to stick out. Every once in a while, a biopharma company discloses perks that go beyond t…Endpoints · 1mo ago↗ source
- Rapport ‘fully prepared’ to launch seizure drug solo, CEO says<p>In a wide-ranging interview, Abe Ceesay detailed how Rapport built an investor syndicate and why the company is confident it can join the ranks of successful, commercial-stage brain drugmakers.</p>